•
Jun 30, 2021
Marinus Pharmaceuticals Q2 2021 Earnings Report
Marinus Pharmaceuticals reported financial results for Q2 2021 and provided a business update.
Key Takeaways
Marinus Pharmaceuticals reported its Q2 2021 financial results and provided an update on its clinical and regulatory development activities. Key highlights include the European collaboration with Orion Corporation and the submission of the NDA for ganaxolone in CDKL5 deficiency disorder.
European collaboration with Orion Corporation was announced.
NDA for ganaxolone in CDKL5 deficiency disorder was submitted.
FDA indicated overall alignment with the design of the TSC Phase 3 clinical trial.
TSC Phase 3 clinical trial is expected to be initiated in the fourth quarter of the year.
Marinus Pharmaceuticals
Marinus Pharmaceuticals
Forward Guidance
Marinus Pharmaceuticals anticipates the remainder of 2021 to be eventful with continued progress in clinical and regulatory development activities.